Valeritas Revenue and Competitors
Estimated Revenue & Valuation
- Valeritas's estimated annual revenue is currently $26.4M per year.
- Valeritas received $23.7M in venture funding in May 2016.
- Valeritas's estimated revenue per employee is $643,854
- Valeritas's total funding is $355M.
Employee Data
- Valeritas has 41 Employees.
- Valeritas grew their employee count by 37% last year.
Valeritas's People
Name | Title | Email/Phone |
---|
Valeritas Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $7.8M | 31 | 11% | N/A | N/A |
#2 | $12.3M | 49 | -4% | N/A | N/A |
#3 | $15.1M | 60 | 7% | N/A | N/A |
#4 | $8.8M | 35 | -8% | N/A | N/A |
#5 | $3M | 12 | 9% | N/A | N/A |
#6 | $300.4M | 1197 | 3% | N/A | N/A |
#7 | $311.7M | 1242 | 2% | N/A | N/A |
#8 | $0.3M | 1 | -96% | N/A | N/A |
#9 | $8.3M | 33 | 3% | N/A | N/A |
#10 | $13.6M | 54 | 8% | N/A | N/A |
What Is Valeritas?
We are a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. We designed our first commercialized product, the V-Go Wearable Insulin Delivery Device, or V-Go, to help patients with Type 2 diabetes who require insulin to achieve and maintain their target blood glucose goals. V-Go is indicated for continuous subcutaneous infusion of insulin over 24 hours at preset rates and on-demand bolus dosing in two-unit increments in adult patients requiring insulin. V-Go is a small, discreet and easy-to-use disposable insulin delivery device that a patient adheres to his or her skin every 24 hours. V-Go enables patients to manage their diabetes with insulin without the need to plan a daily routine around multiple daily injections. V-Go enables patients to closely mimic the body's normal physiologic pattern of insulin delivery by using one type of insulin (fast-acting) at a continuous preset (background) basal rate over a 24-hour period and provides on-demand bolus dosing for meals and snacks. In numerous real-world analyses V-Go has consistently shown to lower A1C's with less insulin. The discreet and convenient basal-bolus insulin delivery method provided by V-Go empowers patients to simplify their insulin management thereby mitigating the need to plan their daily routine around multiple daily injections. V-Go is cleared for use in the United States and the E.U. is commercially available in the United States.
keywords:Biotechnology,Healthcare,Medical Devices,Pharmaceuticals$355M
Total Funding
41
Number of Employees
$26.4M
Revenue (est)
37%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Valeritas News
Valeritas, SteadyMed Therapeutics, Tandem Diabetes Care, Amgen, Medtronic, Insulet Corporation, United Therapeutic Corporation,...
... Tandem Diabetes Care, CeQur, F Hoffmann-La Roche, Insulet Corporation, Ypsomed, Sooil Development, Cellenovo, Valeritas Inc.
... International Technology, National Medical Products, Valeritas, European Pharma Group, PenJet Corporation, Becton, Dickinson.
BRIDGEWATER, N.J., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and ...
BRIDGEWATER, N.J., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $4.1M | 41 | -33% | $85M |
#2 | $10.6M | 41 | 8% | N/A |
#3 | $4.9M | 41 | -7% | N/A |
#4 | $7.4M | 44 | -10% | N/A |
#5 | $8.8M | 44 | -14% | N/A |
Valeritas Funding
Date | Amount | Round | Lead Investors | Reference |
---|---|---|---|---|
2008-11-11 | $50.0M | Undisclosed | Article | |
2011-09-13 | $150.0M | C | Welsh Carson Anderson and Stow | Article |
2013-06-05 | $100.0M | Undisclosed | Capital Royalty L P | Article |
2016-05-05 | $23.7M | Undisclosed | CRG L.P | Article |